High-risk patients were enrolled in this cohort, including 17 with extramedullary disease (EMD) (11 with CNS disease), 10 with BCR-ABL+, 8 with TP53 mutation, and 11 with relapsed ALL after allo-HSCT. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.